CME Regional Glaucoma Program: Innovations in Glaucoma, What's New, What's Really True. Register Now!

March 8, 2005

regionals

EARN 4.5 CME CREDITS!

CME REGIONAL MEETINGS


7:30 AM - 2:00 PM
COMPLIMENTARY CME CREDIT
BREAKFAST, AND LUNCH

Click here for Hotel Accommodations

REGISTER ON-LINE NOW!

AGENDA

FACULTY

REGISTRATION

Target Audience:


This educational activity is intended for general ophthalmologists, glaucoma specialists, and resident ophthalmologists.

Program Description
Glaucoma is a potentially blinding but treatable optic neuropathy, and it is the leading cause of vision loss worldwide. In recent years, diagnostic and therapeutic advances have greatly expanded the number of tools available to evaluate and treat glaucoma. It is well established that structural optic nerve damage precedes functional visual field loss, but new tests of structure and function offer the possibility of earlier diagnosis. Treatment options for patients with established glaucoma continue to expand, from new medications to new laser procedures to innovative surgical options. The emergence of so many new diagnostic and therapeutic modalities within a relatively short time period has generated both clinical excitement and uncertainty. The optimal use of these new technologies has not yet been established. In this program, new diagnostic and therapeutic options will be thoroughly reviewed, with an emphasis on incorporating them into everyday clinical practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the diagnostic applications of optic nerve head imaging devices


  • Incorporate central corneal thickness measurements into clinical practice


  • Describe the role of new visual field testing strategies in the diagnosis of early glaucoma


  • Discuss the similarities and differences of argon and selective laser trabeculoplasty


  • Identify indications for implantation of glaucoma drainage devices


  • Select appropriate first-line and adjunctive therapy for individual patients with glaucoma


  • Understand the evidence supporting the European Glaucoma Study treatment guidelines


  • Discuss the methodology and implications of therapeutic persistency data

Accreditation Statement:
This continuing medical education activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The New York Eye and Ear Infirmary and Ophthalmology Times. The New York Eye and Ear Infirmary is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The New York Eye and Ear Infirmary designates this educational activity for a maximum of 4.5 hours of category 1 credit toward the AMA Physician's Recognition Award.

This educational activity is jointly sponsored by

The New York Eye and Ear Infirmary
and

This activity is supported by an educational grant from